Chemistry: molecular biology and microbiology – Enzyme – proenzyme; compositions thereof; process for... – Hydrolase
Reexamination Certificate
2001-03-06
2003-03-18
Nashed, Nashaat T. (Department: 1652)
Chemistry: molecular biology and microbiology
Enzyme , proenzyme; compositions thereof; process for...
Hydrolase
C435S325000, C435S252330, C435S320100, C536S023200, C536S023500
Reexamination Certificate
active
06534301
ABSTRACT:
BACKGROUND OF THE INVENTION
Members of the phospholipase C family of enzymes are key mediators of cellular signal transduction. Many extracellular signaling molecules including hormones, growth factors, neurotransmitters, and immunoglobulins bind to their respective cell surface receptors and activate phospholipase C enzymes. In general, biological systems that are activated by receptor tyrosine kinase function in part by effecting the activation of an phospholipase-C enzyme. Activated phospholipase C then catalyzes the hydrolysis of phosphatidyl-inositol-4,5-bisphosphate (PIP2), a component of the plasma membrane, to produce diacylglycerol and inositol 1,4,5-trisphosphate (IP3).
In their respective biochemical pathways, IP3 and diacylglycerol serve as second messengers that trigger a series of intracellular responses. IP3 induces the release of calcium from intracellular stores, and diacylglycerol activates protein kinase C (PKC). The calcium ions directly regulate target enzymes and indirectly affect other enzymes by functioning as a second messenger and interacting with calcium-binding proteins, such as troponin C and calmodulin. For example, calcium ions regulate muscle contraction, glycogen breakdown and exocytosis. Diacylglycerol, a product of the hydrolysis by PLCs, acts as a second messenger by activating protein kinase C. Activated protein kinase C phosphorylates a number of intracellular proteins at the serine and threonine residues to thereby regulate downstream intracellular signalling. For example, the phosphorylation of glycogen synthase by protein kinase C inhibits the synthesis of glycogen. Protein kinase C can also control cell division and proliferation.
Both the calcium and the PKC pathways are major branches of transmembrane signal transduction circuits, which regulate numerous cellular processes, including secretion, neural activity, metabolism, and proliferation. Hence, phospholipase C molecules have many regulatory functions including: regulation of glycogenolysis in liver cells, histamine secretion by mast cells, serotonin release by blood platelets, aggregation by blood platelets, insulin release by pancreatic islet cells, epinephrine secretion by adrenal chromaffin cells, and smooth muscle contraction. Evidence indicates that a high percentage of primary human mammary carcinomas concomitantly show abnormally high levels of PLC-gamma-1 (Kassis et al.,
Clin Cancer Res
., Aug;5(8):2251-60, 1999). Likewise, studies on spontaneous hypertensive rats have suggested that one of the main causes for the hypertension is an abnormal activation of PLC-delta-1 resulting from point mutations in the X and Y regions of the PLC amino acid sequence (Sanada et al.,
Hypertension
33(4):1036-42, 1999).
Phospholipase C molecules have been found in a broad spectrum of organisms including bacteria, simple eukaryotes, plants and animals (Munnik et al.(1998)
Biochim. Biophys. Acta.
1389:222-272,). Several distinct isoforms of phospholipase C have been identified in animals and are categorized as PLC-&bgr;, PLC-&ggr;, and PLC-&dgr;. Subtypes are designated by adding Arabic numbers after the Greek letters, e.g., PLC-&bgr;1. PLCs have a molecular mass of 62-68 kDa, and their amino acid sequences show two regions of significant similarity.
SUMMARY OF THE INVENTION
The present invention is based, in part, on the discovery of a novel phospholipase C family member, referred to herein as “16835”. The nucleotide sequence of a cDNA encoding 16835 is shown in SEQ ID NO:1, and the amino acid sequence of a 16835 polypeptide is shown in SEQ ID NO:2. In addition, the nucleotide sequences of the coding region are depicted in SEQ ID NO:3.
Accordingly, in one aspect, the invention features a nucleic acid molecule which encodes a 16835 protein or polypeptide, e.g., a biologically active portion of the 16835 protein. In a preferred embodiment the isolated nucleic acid molecule encodes a polypeptide having the amino acid sequence of SEQ ID NO:2. In other embodiments, the invention provides isolated 16835 nucleic acid molecules having the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3, or the sequence of the DNA insert of the plasmid deposited with ATCC Accession Numbers 1864 and 1865. In still other embodiments, the invention provides nucleic acid molecules that are substantially identical (e.g., naturally occurring allelic variants) to the nucleotide sequence shown in SEQ ID NO:1, SEQ ID NO:3. or the sequence of the DNA insert of the plasmid deposited with ATCC Accession Numbers 1864 and 1865. In other embodiments, the invention provides a nucleic acid molecule which hybridizes under a stringency condition described herein to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, 3, or the sequence of the DNA insert of the plasmid deposited with ATCC Accession Numbers 1864 and 1865, wherein the nucleic acid encodes a full length 16835 protein or an active fragment thereof.
In a related aspect, the invention further provides nucleic acid constructs which include a 16835 nucleic acid molecule described herein. In certain embodiments, the nucleic acid molecules of the invention are operatively linked to native or heterologous regulatory sequences. Also included, are vectors and host cells containing the 16835 nucleic acid molecules of the invention e.g., vectors and host cells suitable for producing 16835 nucleic acid molecules and polypeptides.
In another related aspect, the invention provides nucleic acid fragments suitable as primers or hybridization probes for the detection of 16835-encoding nucleic acids.
In still another related aspect, isolated nucleic acid molecules that are antisense to a 16835 encoding nucleic acid molecule are provided.
In another aspect, the invention features, 16835 polypeptides, and biologically active or antigenic fragments thereof that are useful, e.g., as reagents or targets in assays applicable to treatment and diagnosis of 16835-mediated or -related disorders. In another embodiment, the invention provides 16835 polypeptides having a 16835 activity. Preferred polypeptides are 16835 proteins including at least one phospholipase C domain (e.g., a PLC-X domain (from about amino acids 285-430 of SEQ ID NO:2) and a PLC-Y domain (from about amino acids 474-591 of SEQ ID NO:2)), a calcium binding (C2) domain (from about amino acids 609-699 of SEQ ID NO:2), and/or a pleckstrin homology (PH) domain (from about amino acids 11-119 of SEQ ID NO:2), and, preferably, having a 16835 activity, e.g., an activity as described herein, e.g., the ability to catalyze the hydrolysis of phosphatidylinositol-4,5-bisphosphate (PIP2) producing diacylglycerol and inositol 1,4,5-trisphosphate (IP3).
In other embodiments, the invention provides 16835 polypeptides, e.g., a 16835 polypeptide having the amino acid sequence shown in SEQ ID NO:2 or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC Accession Numbers 1864 and 1865; an amino acid sequence that is substantially identical to the amino acid sequence shown in SEQ ID NO:2 or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC Accession Numbers 1864 and 1865; or an amino acid sequence encoded by a nucleic acid molecule having a nucleotide sequence which hybridizes under a stringency condition described herein to a nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:1, SEQ ID NO:3, or the sequence of the DNA insert of the plasmid deposited with ATCC Accession Numbers 1864 and 1865, wherein the nucleic acid encodes a full length 16835 protein or an active fragment thereof.
In a related aspect, the invention further provides nucleic acid constructs which include a 16835 nucleic acid molecule described herein.
In a related aspect, the invention provides 16835 polypeptides or fragments operatively linked to non-16835 polypeptides to form fusion proteins. In another aspect, the invention features antibodies and antigen-binding fragments thereof, that react with, or more preferably specifically bind 16835 polypeptides.
In another a
Millennium Pharmaceuticals Inc.
Nashed Nashaat T.
LandOfFree
16835, a novel human phospholipase C family member and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 16835, a novel human phospholipase C family member and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 16835, a novel human phospholipase C family member and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3065638